Zentalis Pharmaceuticals (NASDAQ:ZNTL) Issues Quarterly Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.09, Zacks reports. The company had revenue of $26.90 million during the quarter.

Zentalis Pharmaceuticals Trading Down 12.2 %

Shares of NASDAQ ZNTL traded down $0.22 during trading hours on Monday, hitting $1.59. 966,995 shares of the company traded hands, compared to its average volume of 1,532,670. The company's 50 day moving average price is $2.02 and its 200 day moving average price is $2.84. Zentalis Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $16.27. The stock has a market capitalization of $114.18 million, a price-to-earnings ratio of -0.64 and a beta of 1.75.

Insider Buying and Selling

In other news, insider Ingmar Bruns acquired 20,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Thursday, February 6th. The shares were bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the transaction, the insider now directly owns 36,629 shares of the company's stock, valued at $83,514.12. This trade represents a 120.27 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Jan Skvarka bought 60,000 shares of the company's stock in a transaction on Friday, January 31st. The shares were acquired at an average price of $1.72 per share, with a total value of $103,200.00. Following the transaction, the director now directly owns 149,551 shares of the company's stock, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Wedbush reiterated a "neutral" rating and issued a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday. UBS Group cut their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Wells Fargo & Company decreased their target price on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of "Hold" and an average price target of $8.24.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.